contemporarypediatrics2 天
Discussing atopic dermatitis, roflumilast cream 0.15% with Russell Libby, MD, FAAP
Russell Libby, MD, FAAP highlights some key benefits of roflumilast 0.15%, approved in 2024 to treat AD in patients aged 6 years and older. Atopic dermatitis (AD) remains a persistent challenge for ...
contemporarypediatrics3 天
Maria D McColgan, MD, MSEd, FAAP
Keeping up with type 1 diabetes technology changes in primary care ...
contemporarypediatrics3 天
Nadine Peart Akindele, MD
Keeping up with type 1 diabetes technology changes in primary care ...
contemporarypediatrics3 天
J. Freeman King, EdD
Keeping up with type 1 diabetes technology changes in primary care ...
contemporarypediatrics4 天
Mick Connors, MD, FAAP
Keeping up with type 1 diabetes technology changes in primary care ...
contemporarypediatrics5 天
Discussing FDA approved neffy with Russell Libby, MD, FAAP
Contemporary Pediatrics' editorial advisory member Russell Libby, MD, FAAP, highlights 2024 FDA approval of epinephrine nasal spray (Neffy) in this video interview. A new needle-free epinephrine ...
contemporarypediatrics4 天
Michele Cheung
Keeping up with type 1 diabetes technology changes in primary care ...
contemporarypediatrics9 天
2024’s critical needle-free approvals for pediatric anaphylaxis, influenza
Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care. In the pediatric population, it is no ...
contemporarypediatrics6 天
Wael N. Sayej, MD
Keeping up with type 1 diabetes technology changes in primary care ...
contemporarypediatrics6 天
Dawen Chen, PharmD candidate
Keeping up with type 1 diabetes technology changes in primary care ...
contemporarypediatrics6 天
Charles J. Hyman, MD, FAAP
Keeping up with type 1 diabetes technology changes in primary care ...
contemporarypediatrics6 天
John Rusher, MD, JD, FAAP
Keeping up with type 1 diabetes technology changes in primary care ...